
Annovis Bio Reports Positive Results from Final Phase of $1.9M NIH Funded Chronic Toxicology Study
BERWYN, PA — Annovis Bio Inc. (NYSE American: ANVS), a clinical-stage drug platform company addressing Alzheimer’s disease (AD), Parkinson’s disease (PD) and other neurodegenerative diseases, announced it successfully completed the …
Read More